110 related articles for article (PubMed ID: 17294385)
1. Long-term follow-up of tacrolimus treatment in immune posterior uveitis.
Figueroa MS; Ciancas E; Orte L
Eur J Ophthalmol; 2007; 17(1):69-74. PubMed ID: 17294385
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis.
Kilmartin DJ; Forrester JV; Dick AD
Ocul Immunol Inflamm; 1998 Jun; 6(2):101-9. PubMed ID: 9689640
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine.
Sloper CM; Powell RJ; Dua HS
Ophthalmology; 1999 Apr; 106(4):723-8. PubMed ID: 10201592
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis.
Murphy CC; Greiner K; Plskova J; Duncan L; Frost NA; Forrester JV; Dick AD
Arch Ophthalmol; 2005 May; 123(5):634-41. PubMed ID: 15883282
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
[TBL] [Abstract][Full Text] [Related]
6. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
[TBL] [Abstract][Full Text] [Related]
7. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
[TBL] [Abstract][Full Text] [Related]
8. Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis.
Murphy CC; Greiner K; Plskova J; Frost NA; Forrester JV; Dick AD
Br J Ophthalmol; 2007 Feb; 91(2):154-6. PubMed ID: 16973657
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis.
Hogan AC; McAvoy CE; Dick AD; Lee RW
Ophthalmology; 2007 May; 114(5):1000-6. PubMed ID: 17467532
[TBL] [Abstract][Full Text] [Related]
12. LONG-TERM OUTCOMES OF RITUXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS POSTERIOR UVEITIS REFRACTORY TO CONVENTIONAL IMMUNOSUPPRESSIVE THERAPY.
Lasave AF; You C; Ma L; Abusamra K; Lamba N; Valdes Navarro M; Meese H; Foster CS
Retina; 2018 Feb; 38(2):395-402. PubMed ID: 28225369
[TBL] [Abstract][Full Text] [Related]
13. Noninfectious uveitis: a scarcity of randomized clinical trials.
Okada AA
Arch Ophthalmol; 2005 May; 123(5):682-3. PubMed ID: 15883289
[No Abstract] [Full Text] [Related]
14. Quantification of the ocular response to treatment in posterior uveitis.
Ferguson VM; Spalton DJ
Acta Ophthalmol (Copenh); 1992 Dec; 70(6):824-31. PubMed ID: 1488895
[TBL] [Abstract][Full Text] [Related]
15. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
17. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
[TBL] [Abstract][Full Text] [Related]
18. Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study.
Shihab FS; Waid TH; Conti DJ; Yang H; Holman MJ; Mulloy LC; Henning AK; Holman J; First MR;
Transplantation; 2008 May; 85(9):1261-9. PubMed ID: 18475181
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis.
Al-Amri AM
Am J Ophthalmol; 2014 Feb; 157(2):280-6. PubMed ID: 24439439
[TBL] [Abstract][Full Text] [Related]
20. Conversion to tacrolimus extended-release formulation: short-term clinical results.
Gallego-Valcarce E; Ortega-Cerrato A; Llamas-Fuentes F; Martinez-Fernandez G; Perez-Martinez J; Gomez-Roldan C
Transplant Proc; 2009; 41(6):2326-7. PubMed ID: 19715909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
